Can Fite Biofarma (Can Fite Biofarma) Price-to-Operating-Cash-Flow

: (As of Today)

View and export this data going back to 2012. Start your Free Trial

As of today (2024-04-17), Can Fite Biofarma's share price is $1.96. Can Fite Biofarma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Can Fite Biofarma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Can Fite Biofarma's Price-to-Operating-Cash-Flow or its related term are showing as below:

CANF's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.05
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Can Fite Biofarma's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 41.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 45.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 36.00% per year.

During the past 13 years, Can Fite Biofarma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 53.20% per year. The lowest was -14.40% per year. And the median was 22.40% per year.

Can Fite Biofarma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Can Fite Biofarma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Price-to-Operating-Cash-Flow falls into.

Can Fite Biofarma Price-to-Operating-Cash-Flow Calculation

Can Fite Biofarma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.96	/	0
	=

Can Fite Biofarma's Share Price of today is $1.96.
Can Fite Biofarma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Can Fite Biofarma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).